Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Notes_NNP 000_CD 000_CD Turnover_NN 2_CD 69,573_CD 46,126_CD Cost_NN of_IN sales_NNS 2_CD 24,830_CD 18,820_CD Gross_NNP profit_NN 44,743_CD 27,306_CD Selling_NNP ,_, marketing_NN and_CC distribution_NN expenses_NNS 4,769_CD 4,804_CD Administration_NN expenses_NNS Amortisation_NNP 6,506_CD 3,824_CD Other_JJ administration_NN expenses_NNS 13,686_CD 12,201_CD 20,192_CD 16,025_CD Research_NNP and_CC development_NN expenses_NNS 29,285_CD 17,918_CD Other_JJ operating_NN income_NN 3_CD 14,219_CD 6,342_CD Operating_NN profit_NN loss_NN 2,4_CD 4,716_CD 5,099_CD Associated_NNP undertaking_NN Share_NN of_IN loss_NN of_IN associated_VBN undertaking_NN 75_CD Amortisation_NNP of_IN goodwill_NN 503_CD 578_CD Total_JJ operating_NN profit_NN loss_NN :_: Group_NNP and_CC share_NN of_IN associates_NNS 4,716_CD 5,677_CD Interest_NN receivable_NN 6_CD 1,081_CD 1,251_CD Interest_NN payable_JJ 7_CD 4,464_CD 4,951_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 1,333_CD 9,377_CD Taxation_NNP 8_CD 224_CD 75_CD Retained_VBN profit_NN loss_NN 1,109_CD 9,452_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP 9_CD Basic_JJ 0.2_CD p_NN 1.8_CD p_NN Diluted_NNP 0.2_CD p_NN 1.8_CD p_NN There_EX was_VBD no_DT material_NN difference_NN between_IN the_DT profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN and_CC the_DT historical_JJ cost_NN profit_NN loss_NN before_IN taxation_NN in_IN 2002_CD and_CC 2001_CD ._.
All_DT results_NNS represent_VBP continuing_VBG activities_NNS ._.
See_VB Notes_NNS to_TO the_DT Financial_NNP Statements_NNP consolidated_JJ profit_NN 50_CD and_CC loss_NN account_NN SkyePharma_NNP annual_JJ report_NN 2002_CD
